Search - tctmd.com

Displaying 981 - 1000 of 1574

Sort: Relevancy | Date

News Conference News TCT 2016

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Yael L. Maxwell

November 02, 2016

Presentation TCT 2016

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Presenter: Martin B. Leon, Louis A. Cannon, Sean P. Lyden

November 02, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Andreas Baumbach

November 01, 2016

Presentation TCT 2016

What Should Be the Next Series of Clinical Trials in PFO Closure?

Presenter: Eustaquio Maria Onorato, Richard Smalling, John D. Carroll

November 01, 2016

Presentation TCT 2016

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

Presenter: John D. Carroll, Christian Spies

November 01, 2016

Presentation TCT 2016

To Pretreat or Not to Pretreat? The DUBIUS Trial

Presenter: Roxana Mehran, Ferdinando Varbella, Giuseppe Tarantini

November 01, 2016

Presentation TCT 2016

Accurate: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Helge Möllmann

November 01, 2016

News Conference News TCT 2016

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Todd Neale

November 01, 2016

Presentation TCT 2016

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Azeem Latib

November 01, 2016

News Industry News TCT 2016

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

November 01, 2016

Presentation TCT 2016

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Ted Feldman

November 01, 2016

Presentation TCT 2016

Portico: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Raj Makkar

November 01, 2016

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

Presentation TCT 2016

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., John G. Webb

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2016

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Presenter: Robert O. Bonow, Mitchell W. Krucoff, Manesh R. Patel

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

Advertisement

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

ILLUMENATE U.S.: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs an Uncoated Balloon for Treatment of Diseased Superficial Femoral and Popliteal Arteries

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

What Should Be the Next Series of Clinical Trials in PFO Closure?

What Do the Randomized Clinical Trials Tell Us and How Did the FDA Respond?

To Pretreat or Not to Pretreat? The DUBIUS Trial

Accurate: Design Features, Special Attributes, and Clinical Trial Program

Midterm Durability of TAVR Valves: PARTNER, Other Studies Boost Confidence

Direct Flow: Design Features, Special Attributes, and Clinical Trial Program

Study Finds No Long-Term Clinical Benefit to Routine Follow-Up Coronary Angiography After PCI

Lotus and EDGE: Design Features, Special Attributes, and Clinical Trial Program

Portico: Design Features, Special Attributes, and Clinical Trial Program

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Sapien 3 and ULTRA: Design Features, Special Attributes, and Clinical Trial Program

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Featured Lecture: Balancing the Needs for Data Transparency and the Clinical Trial Enterprise

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content